159622-09-0

Basic information

• Product Name: methyl ester, (1R,2S)-
• Synonyms: methyl ester, (1R,2S)-;methyl (1R,2S)-1-[(tert-butoxycarbonyl)amino]-2-vinylcyclopropanecarboxylate;Cyclopropanecarboxylic acid, 1-[[(1,1-diMethylethoxy)carbonyl]aMino]-2-ethenyl-, Methyl ester, (1R,2S)-;(1R,2S)-1-[[(1,1-DiMethylethoxy)Carbonyl]AMino]-2-Ethenyl-Cyclopropanecarboxylic Acid Methyl Ester;(1R,2S)-Methyl 1-(tert-butoxycarbonylamino)- 2-vinylcyclopropanecarboxylate
• CAS NO: 159622-09-0
• Molecular Formula: C₁₂H₁₉NO₄
• Molecular Weight: 241.285
• Mol File: 159622-09-0.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 312.253°C at 760 mmHg
• Flash Point: 142.646°C
• Appearance: /
• Density: 1.101g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.484
• Storage Temp.: 2-8°C
• CAS DataBase Reference: methyl ester, (1R,2S)-(CAS DataBase Reference)
• NIST Chemistry Reference: methyl ester, (1R,2S)-(159622-09-0)
• EPA Substance Registry System: methyl ester, (1R,2S)-(159622-09-0)

Safety Data

• Hazardous Substances Data: 159622-09-0(Hazardous Substances Data)

Usage

General Description

Methyl ester, (1R,2S)- is a chemical compound with the molecular formula C4H8O2. It is a chiral compound, meaning it has non-superimposable mirror images. The (1R,2S)- designation indicates that in its three-dimensional structure, the methyl ester has a specific arrangement of atoms. methyl ester, (1R,2S)- is commonly used as a building block in organic synthesis, particularly in the production of pharmaceuticals, fragrances, and flavorings. Its chiral nature gives it unique properties and potential applications in the field of asymmetric synthesis. Additionally, it can also be used as a solvent or as an intermediate in chemical reactions.

InChI:InChI=1/C12H19NO4/c1-6-8-7-12(8,9(14)16-5)13-10(15)17-11(2,3)4/h6,8H,1,7H2,2-5H3,(H,13,15)/t8-,12-/m1/s1

Upstream product

• 159622-10-3 (1R,2S)-1-(tert-butoxycarbonylamino)-2-vinylcyclopropanecarboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 24424-99-5 di-tert-butyl dicarbonate 
• 159700-58-0 (1R,2S)-2-vinyl-1-aminocyclopropanecarboxylic acid 
• 915317-20-3 C₁₂H₁₉NO₄ 
• 259214-58-9 (1S,2S)-1-amino-2-vinylcyclopropane carboxylic acid methyl-ester hydrochloride 
• 159700-59-1 (1S,2S)-1-carbomethoxy-2-vinylcyclopropane-1-carboxylic acid 
• 17447-60-8 dimethyl 2-vinylcyclopropane-1,1-dicarboxylate 
• 213316-49-5 (1RS,2SR)-ethyl 2-vinyl-1-(tert-butoxycarbonylamino)cyclopropanecarboxylate 
• 213316-32-6 rac-(1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid ethyl ester 
• 67-56-1 methanol 
• 1201943-62-5 1-tert-butoxycarbonylamino-2-vinylcyclopropanecarboxylic acid methyl ester 
• 159622-08-9 (1S,2S)-1-Azidocarbonyl-2-vinyl-cyclopropanecarboxylic acid methyl ester 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 853269-57-5 tert-butyl [(1R,2S)-2-ethenyl-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]carbamate 
• 1201943-62-5 (1R,2R)-methyl 1-t-butoxycarbonylamino-2-vinylcyclopropane carboxylate 
• 862273-27-6 (1R,2S)-1-amino-2-vinylcyclopropane carboxylic acid methyl ester tosylate salt 
• 159622-10-3 (1R,2S)-1-(tert-butoxycarbonylamino)-2-vinylcyclopropanecarboxylic acid 
• 862273-27-6 (1R,2R)-methyl 1-amino-2-vinylcyclopropane carboxylate tosylate salt 

Relevant articles and documents

A TEIXOBACTIN ANALOGUE AND USE THEREOF

Provided herein belongs to the field of pharmaceuticals, and specifically relates to a Teixobactin analogue and use thereof. It further relates to a pharmaceutical composition comprising the compound and use of the compound and the pharmaceutical composit

Asymmetric synthesis of (1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid by sequential SN2-SN2′ dialkylation of (R)-N-(benzyl)proline-derived glycine Schiff base Ni(ii) complex

This work describes a new process for the asymmetric synthesis of (1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid of high pharmaceutical importance. The sequence of the reactions includes PTC alkylation (SN2), homogeneous SN2′ cyclization followed by disassembly of the resultant Ni(ii) complex. All reactions are conducted under operationally convenient conditions and suitably scaled up to 6 g of the starting Ni(ii) complex. This journal is

INHIBITORS OF SERINE PROTEASES FOR THE TREATMENT OF HCV INFECTIONS

The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof. These compounds inhibit serine protease, particularly the hepatitis C virus NS3-NS4A protease.